TREVENA INC
TRVN evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for TRVN—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper Score
Based on 4 of 6 signals
Financial data as of Sep 30, 2024.
Tracking 3 pipeline candidates · 1 FDA decision for TREVENA INC.
Run TREVENA INC through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available TREVENA INC facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Score breakdownBased on 4 of 6 signals · derived from public data
9.5 months
OCF -$5M · Net income -$5M
Lead: Approved
3 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Pipeline
Regulatory
Financials
Short Interest
as of May 1, 2026- % of float
- 7.0%
- Days to cover
- 1.0
- Shares short
- 59,358
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
TRVN short interestGovernance
Frequently asked questions
What is TREVENA INC's lead drug candidate?
TREVENA INC's most advanced tracked candidate is olinvyk (Approved) for management of acute pain severe enough to require an intravenous opioid analgesic and for whom alternative treatments are inadequate.
Who is the CEO of TREVENA INC?
Ms. Carrie L. Bourdow is the chief executive officer of TREVENA INC (TRVN).
Where is TREVENA INC headquartered?
TREVENA INC (TRVN) is headquartered in Chesterbrook, PA, United States.
What therapeutic areas does TREVENA INC focus on?
TREVENA INC develops therapies across Neurology, Pain, Psychiatry.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.